Literature DB >> 32041746

Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications.

T Kissel1, S Reijm2, L M Slot2, M Cavallari3, C M Wortel2, R D Vergroesen2, G Stoeken-Rijsbergen2, J C Kwekkeboom2, Asb Kampstra2, Ewn Levarht2, J W Drijfhout4, H Bang5, K M Bonger6, Gmc Janssen7, P A van Veelen7, Twj Huizinga2, H U Scherer2, M Reth3, Rem Toes2.   

Abstract

OBJECTIVE: Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The relation between these anti-modified protein antibody (AMPA)-classes is poorly understood as is the ability of different PTM-antigens to activate B-cell receptors (BCRs) directed against citrullinated proteins (CP). Insights into the nature of PTMs able to activate such B cells are pivotal to understand the 'evolution' of the autoimmune response conceivable underlying the disease. Here, we investigated the cross-reactivity of monoclonal AMPA and the ability of different types of PTM-antigens to activate CP-reactive BCRs.
METHODS: BCR sequences from B cells isolated using citrullinated or acetylated antigens were used to produce monoclonal antibodies (mAb) followed by a detailed analysis of their cross-reactivity towards PTM-antigens. Ramos B-cell transfectants expressing CP-reactive IgG BCRs were generated and their activation on stimulation with PTM-antigens investigated.
RESULTS: Most mAbs were highly cross-reactive towards multiple PTMs, while no reactivity was observed to the unmodified controls. B cells carrying CP-reactive BCRs showed activation on stimulation with various types of PTM-antigens.
CONCLUSIONS: Our study illustrates that AMPA exhibit a high cross-reactivity towards at least two PTMs indicating that their recognition pattern is not confined to one type of modification. Furthermore, our data show that CP-reactive B cells are not only activated by citrullinated, but also by carbamylated and/or acetylated antigens. These data are vital for the understanding of the breach of B-cell tolerance against PTM-antigens and the possible contribution of these antigens to RA-pathogenesis. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  B cells; autoantibodies; rheumatoid arthritis

Year:  2020        PMID: 32041746     DOI: 10.1136/annrheumdis-2019-216499

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Cross-reactive autoantibodies in RA.

Authors:  Jessica McHugh
Journal:  Nat Rev Rheumatol       Date:  2020-04       Impact factor: 20.543

Review 2.  The current status of anti-citrullinated protein antibodies and citrullinated protein-reactive B cells in the pathogenesis of rheumatoid arthritis.

Authors:  Jia He; JiYu Ju; XiaoDong Wang
Journal:  Mol Biol Rep       Date:  2021-12-02       Impact factor: 2.316

Review 3.  From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Diane van der Woude; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2022-05-23       Impact factor: 32.286

4.  Rheumatoid Factor and Anti-Modified Protein Antibody Reactivities Converge on IgG Epitopes.

Authors:  Aisha M Mergaert; Zihao Zheng; Michael F Denny; Maya F Amjadi; S Janna Bashar; Michael A Newton; Vivianne Malmström; Caroline Grönwall; Sara S McCoy; Miriam A Shelef
Journal:  Arthritis Rheumatol       Date:  2022-04-10       Impact factor: 15.483

Review 5.  The immunology of rheumatoid arthritis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Nat Immunol       Date:  2020-11-30       Impact factor: 25.606

Review 6.  Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives.

Authors:  Johan Rönnelid; Carl Turesson; Alf Kastbom
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 7.  Redox-Mediated Carbamylation As a Hapten Model Applied to the Origin of Antibodies to Modified Proteins in Rheumatoid Arthritis.

Authors:  Maria Isabel Trejo-Zambrano; Eduardo Gómez-Bañuelos; Felipe Andrade
Journal:  Antioxid Redox Signal       Date:  2021-06-04       Impact factor: 7.468

8.  Generation of Monoclonal Antibodies Specific for Native LL37 and Citrullinated LL37 That Discriminate the Two LL37 Forms in the Skin and Circulation of Cutaneous/Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients.

Authors:  Roberto Lande; Raffaella Palazzo; Philippe Hammel; Immacolata Pietraforte; Isabelle Surbeck; Michel Gilliet; Carlo Chizzolini; Loredana Frasca
Journal:  Antibodies (Basel)       Date:  2020-05-11

Review 9.  Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.

Authors:  Fenne Wouters; Marc P Maurits; Laurette van Boheemen; Marloes Verstappen; Kulveer Mankia; Xanthe M E Matthijssen; Annemarie L Dorjée; Paul Emery; Rachel Knevel; Dirkjan van Schaardenburg; René E M Toes; Annette H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2021-07-20       Impact factor: 19.103

10.  A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis.

Authors:  Caroline Grönwall; Lisa Liljefors; Holger Bang; Aase H Hensvold; Monika Hansson; Linda Mathsson-Alm; Lena Israelsson; Vijay Joshua; Anna Svärd; Ragnhild Stålesen; Philip J Titcombe; Johanna Steen; Luca Piccoli; Natalia Sherina; Cyril Clavel; Elisabet Svenungsson; Iva Gunnarsson; Saedis Saevarsdottir; Alf Kastbom; Guy Serre; Lars Alfredsson; Vivianne Malmström; Johan Rönnelid; Anca I Catrina; Karin Lundberg; Lars Klareskog
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.